Thrombocytopenia Pipeline Experiences Momentum DelveInsight Estimates a Diverse Pipeline Comprising 27 Companies Working in the Domain
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
About 56% of CTi Biopharma's investor base is looking to short. The analysis of current outlook of investing in CTi Biopharma Corp suggests that many traders are alarmed regarding CTi Biopharma's prospects. The current market sentiment, together with CTi Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use CTi Biopharma Corp stock news signals to limit their universe of possible portfolio assets.
CTi |
The prevalence of thrombocytopenia has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Thrombocytopenia and the growing research and development activities to develop novel therapies to treat Thrombocytopenia to drive the market. The companies developing the potential therapies in the last stage of development include argenx, HUTCHMED, Takeda, and several others.New York, USA, Jan. 30, 2023 -- Thrombocytop
Read at finance.yahoo.com
 |
CTi Biopharma Fundamental Analysis
We analyze CTi Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTi Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTi Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
CTi Biopharma is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
CTi Biopharma Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CTi Biopharma stock to make a market-neutral strategy. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics with similar companies.
Peers
CTi Biopharma Related Equities
| XFOR | X4 Pharmaceuticals | 13.54 | ||||
| RVPH | Reviva Pharmaceuticals | 11.90 | ||||
| IMMP | Immutep | 11.32 | ||||
| VKTX | Viking Therapeutics | 2.84 | ||||
| CRVS | Corvus Pharmaceuticals | 1.12 | ||||
| TGTX | TG Therapeutics | 0.06 | ||||
| CDTX | Cidara Therapeutics | 1.58 | ||||
| PLX | Protalix Biotherapeutics | 1.64 | ||||
| VSTM | Verastem | 1.80 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.99 | ||||
| PDSB | PDS Biotechnology | 2.80 | ||||
| FBIO | Fortress Biotech | 2.83 | ||||
| MCRB | Seres Therapeutics | 3.23 | ||||
| ELEV | Elevation Oncology | 4.00 | ||||
| RIGL | Rigel Pharmaceuticals | 5.01 | ||||
| IBRX | Immunitybio | 32.11 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |